MX9701606A - Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno. - Google Patents

Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.

Info

Publication number
MX9701606A
MX9701606A MX9701606A MX9701606A MX9701606A MX 9701606 A MX9701606 A MX 9701606A MX 9701606 A MX9701606 A MX 9701606A MX 9701606 A MX9701606 A MX 9701606A MX 9701606 A MX9701606 A MX 9701606A
Authority
MX
Mexico
Prior art keywords
bone loss
strogen
progesterone
combination therapy
prevent bone
Prior art date
Application number
MX9701606A
Other languages
English (en)
Other versions
MXPA97001606A (es
Inventor
David B Maclean
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA97001606A publication Critical patent/MXPA97001606A/es
Publication of MX9701606A publication Critical patent/MX9701606A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion proporciona nuevos procedimientos para inhibir la pérdidaosea, que comprenden administrar a un mamífero en necesidad de dicho tratamiento, una cantidad eficaz de un compuesto de formula I (Ver Formula) en la que R1 y R2 pueden ser iguales o diferentes, a condicion de que, cuando R1 y R2 son iguales, cada uno es un grupo metilo o etilo, y, cuando R1 y R2 son diferentes, uno de ellos es un grupo metilo o etilo y el otro es hidrogeno o un grupo bencilo; o una de sus sales farmacéuticamente aceptables; junto con una progesterona.
MX9701606A 1996-02-28 1997-02-27 Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno. MX9701606A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US012400 1987-02-09
US1240096P 1996-02-28 1996-02-28

Publications (2)

Publication Number Publication Date
MXPA97001606A MXPA97001606A (es) 1998-04-01
MX9701606A true MX9701606A (es) 1998-04-30

Family

ID=21754794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701606A MX9701606A (es) 1996-02-28 1997-02-27 Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.

Country Status (9)

Country Link
US (1) US6057309A (es)
EP (1) EP0791356A1 (es)
JP (1) JPH09315977A (es)
KR (1) KR970061245A (es)
AU (1) AU712656B2 (es)
CA (1) CA2198574A1 (es)
IL (1) IL120263A0 (es)
MX (1) MX9701606A (es)
ZA (1) ZA971718B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
EP1523328A4 (en) * 2002-05-24 2007-10-31 Univ Pennsylvania METHODS AND COMPOSITIONS FOR INHIBITING HIV REPLICATION
WO2017205451A1 (en) * 2016-05-24 2017-11-30 Temple University-Of The Commonwealth System Of Higher Education Novel functionalized n,n-dialkylamino phenyl ethers and their method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
JPH06312930A (ja) * 1993-04-30 1994-11-08 Kuraray Co Ltd 骨粗鬆症治療剤
US5591753A (en) * 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin

Also Published As

Publication number Publication date
AU1496797A (en) 1997-09-04
US6057309A (en) 2000-05-02
AU712656B2 (en) 1999-11-11
ZA971718B (en) 1998-08-27
IL120263A0 (en) 1997-06-10
KR970061245A (ko) 1997-09-12
CA2198574A1 (en) 1997-08-28
JPH09315977A (ja) 1997-12-09
EP0791356A1 (en) 1997-08-27

Similar Documents

Publication Publication Date Title
MY119403A (en) Novel compounds with analgesic effect.
AU7578894A (en) Methods for inhibiting smooth muscle cell proliferation and restinosis
CY2473B1 (en) New phenanthridines.
TW283645B (es)
UA41355C2 (uk) Засіб для лікування нейро-сніду
AU4950993A (en) Combination of germicidal agents
UA43391C2 (uk) Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію
EP0938317A4 (en) COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
AU3850600A (en) Dalda analogs and their use
CA2198580A1 (en) Combination therapy to treat osteoporosis
MX9709466A (es) Medicamento para inhibir el melanoma.
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
NO984920D0 (no) Sammensetninger omfattende en nitroneforbindelse for anvendelse ved behandling av okulµr inflammasjon
EP0971725A4 (en) METHOD FOR TREATING SCAR TISSUE
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
AU4944899A (en) New pharmaceutically active compounds
EP1067138A4 (en) HYDROXYPROLINE DERIVATIVES
MX9701532A (es) Procedimiento para aumentar los niveles de testosterona.
CA2233677A1 (en) A novel combination of a .beta.-receptor blocker and an opioid
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.
MY118982A (en) Method of reducing tissue damage associated with ischemia